Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant

AIMS: High dose melphalan (HDM) and autologous stem cell transplant (ASCT) is standard of care for multiple myeloma (MM), but there is significant variability in melphalan exposure (area under the plasma drug concentration–time curve, AUC) when using body surface area‐based dosing. Our aim was to es...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Clin Pharmacol
Autores principales: Sweiss, Karen, Vemu, Bhaskar, Hofmeister, Craig C., Wenzler, Eric, Calip, Gregory Sampang, Galvin, John P., Mahmud, Nadim, Rondelli, Damiano, Johnson, Jeremy James, Patel, Pritesh
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7576633/
https://ncbi.nlm.nih.gov/pubmed/32285957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14308
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares